The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2020

Filed:

Dec. 31, 2018
Applicant:

Acea Biosciences, Inc., San Diego, CA (US);

Inventors:

Yama A. Abassi, San Diego, CA (US);

Naichen Yu, San Diego, CA (US);

Josephine Atienza, San Diego, CA (US);

Xiao Xu, San Diego, CA (US);

Xiaobo Wang, San Diego, CA (US);

Assignee:

ACEA Biosciences, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); G01N 33/543 (2006.01); G01N 27/02 (2006.01); C12Q 1/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5041 (2013.01); C12Q 1/002 (2013.01); G01N 27/021 (2013.01); G01N 33/5014 (2013.01); G01N 33/5438 (2013.01); G01N 2333/4716 (2013.01); G01N 2333/705 (2013.01); G01N 2333/91205 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01);
Abstract

A method of identifying a therapeutic compound for treating cancer in a human subject, the method including: providing a device that measures cell-substrate impedance; culturing cancer cells in the at least two wells, wherein the cancer cells are obtained from a human subject and have a receptor tyrosine kinase (RTK) pathway; adding to a first well a proposed therapeutic compound that affects an RTK pathway and an RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells; and determining a difference in impedance or optionally in cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells of the human subject.


Find Patent Forward Citations

Loading…